Tirzepatide Research Guide
Research Overview
Tirzepatide is a synthetic, fatty-acid-modified peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It has been studied extensively in preclinical and clinical metabolic research as a first-in-class co-agonist of two incretin pathways. This is a research compound and is not intended for human consumption.
Structural & Class Overview
Single-chain incretin-mimetic peptide (39 residues) with a C20 fatty diacid moiety enabling albumin binding and extended half-life. Structurally related to native GIP; functions as an imbalanced dual GIPR/GLP-1R agonist, both receptors belonging to the class B G-protein-coupled receptor family.
General Research Interest
Research interest includes dual incretin-receptor signaling and biased agonism, glucose-dependent insulin secretion pathways in laboratory models, hepatic lipid handling in preclinical steatosis models, receptor desensitization kinetics, and comparative pharmacology against selective GLP-1R agonists.
Storage Considerations
Typically supplied as a lyophilized powder. General research handling favors storage of lyophilized material cold and protected from light and moisture; reconstituted solutions are generally kept refrigerated and used within a limited window. For laboratory research handling only.
Testing & Quality Considerations
Quality considerations for a research peptide include HPLC purity analysis, mass-spectrometry identity confirmation of the expected molecular mass, and verification against a batch Certificate of Analysis (COA) prior to use.
References
- Tirzepatide — DrugBank DB15171
- Tirzepatide — PubChem CID 156588324
- Structural determinants of dual incretin receptor agonism by tirzepatide (PMC)
References are provided for scientific context. Linked sources are independent and not affiliated with iNGEN MD.
